CELLINK announces partnership with biotech company Lonza
Swedish bioprinting firm CELLINK has announced it has formed an alliance with Swiss chemicals and biotech company Lonza. Through the agreement, the partners will combine CELLINK’s 3D bioprinting systems and bioinks with Lonza’s primary cells and culture media to offer a complete 3D bioprinting solution for 3D cell culture workflows. The solution is intended for cell biologists and other researchers pushing the boundaries of bioprinting and human tissue generation.
“Everything we do at CELLINK, from live cell imaging to our innovative bioprinting systems and bioinks, is meant to support our customers with the products and services needed for them to more effectively and efficiently research solutions to some of the most important challenges of our time,” commented Ginger Lohman, Biodispensing Product Manager at CELLINK. “Challenges such as cancer therapeutics, regenerative medicine and the testing and development of drugs, to name a few. When it came time to expand our portfolio into complete 3D cell culture workflows, we knew it was critical that we brought the right partner onboard. We’re confident that Lonza is that partner.”
Through the partnership, CELLINK will offer the complete 3D bioprinting solution through its established global sales channels with support from Lonza’s expert logistics processes. The companies hope the offering will help meet a growing demand from cell biology labs for 3D cell culture technologies, which more closely mimic in vivo environments than more traditional 2D cell culture methods.
“Cell biology laboratories are constantly seeking innovative new technologies to enhance their experimental workflows and help deliver on their promise to drive the next research breakthrough,” added Katrin Hoeck, Head of Marketing for Cell Analysis and Testing Solutions at Lonza. “Our broad panel of human-derived primary cells is specifically engineered to enable researchers to develop biological in vitro model systems that more closely reflect disease biology. This new collaboration with CELLINK will enable our customers to build physiologically-relevant 3D models to accelerate target identification/validation, investigation of mechanisms of action and safety testing in drug discovery.”
Lonza’s portfolio of human-derived primary cells will complement CELLINK’s array of bioprinting systems and its universal bioink material. Robust and viable cells are an important part of the bioprinting equation, and Lonza’s products are all ethically sourced and authenticated through quality control testing. Its culture media products are themselves optimized for each cell type to support optimal cell growth.
